8-K: Integer Reports Strong Q3 2025 Growth, Updates Outlook

Integer Holdings Corporation announced robust third-quarter 2025 results with significant sales and profit growth, while updating its full-year 2025 outlook and providing preliminary guidance for 2026 and 2027.

Summary

• Third quarter 2025 sales increased 8% to $468 million, with organic growth of 7% compared to Q3 2024.
• Non-GAAP adjusted operating income rose 14% to $86 million, and non-GAAP adjusted EPS increased 25% to $1.79.
• GAAP operating income decreased 3% to $56 million, while GAAP income from continuing operations increased 9% to $40 million.
• Cardio & Vascular sales grew 15%, driven by new product ramps, acquisitions, and strong neurovascular demand.
• Cardiac Rhythm Management & Neuromodulation sales increased 2.5%, supported by emerging neuromodulation customers.
• Other Markets sales decreased 15.5% due to the planned multi-year portable medical exit.
• Total debt increased $204 million from the end of 2024 to $1.194 billion, primarily for acquisitions and convertible note offering costs, resulting in a leverage ratio of 3.0 times adjusted EBITDA as of September 26, 2025.
• The company updated its 2025 outlook, projecting sales of $1,840 million to $1,854 million and adjusted EPS of $6.29 to $6.43.
• Preliminary 2026 outlook anticipates reported sales to be down 2% to up 2%, and adjusted EPS down 6% to up 5%.
• Preliminary 2027 outlook projects organic sales growth 200 basis points above market.

Sentiment

Score: 7

Explanation: The company reported strong Q3 2025 results with significant growth in sales and adjusted profits, and raised its full-year 2025 outlook. While there are anticipated headwinds for 2026, the long-term outlook for 2027 projects above-market organic growth, indicating confidence in strategic initiatives and product pipeline. The increase in debt for acquisitions and convertible notes is a factor, but the overall tone is positive regarding operational performance and future prospects.

Positives

• Strong sales growth in Q3 2025, up 8% to $468 million, with organic growth of 7%.
• Significant non-GAAP profit growth in Q3 2025: adjusted operating income up 14% to $86 million, adjusted net income up 27% to $63 million, and adjusted EPS up 25% to $1.79.
• Adjusted EBITDA increased 11% to $106 million in Q3 2025.
• Cardio & Vascular segment showed robust growth of 15% (8.5% organic), driven by new product launches and acquisitions.
• Updated 2025 outlook projects continued growth: sales 7% to 8% higher, adjusted operating income 12% to 14% higher, and adjusted EPS 19% to 21% higher.
• Anticipated return to 200 basis points above-market organic growth in 2027, supported by strategy and product development pipeline.
• Cash and cash equivalents increased to $58,944k as of September 26, 2025, from $46,543k at December 31, 2024.

Negatives

• GAAP operating income decreased 3% to $56 million in Q3 2025.
• GAAP income from continuing operations for the nine months ended September 26, 2025, decreased 38.4% to $54,222k compared to $88,080k in the prior year.
• GAAP diluted EPS from continuing operations for the nine months ended September 26, 2025, decreased 39.0% to $1.52 compared to $2.49 in the prior year.
• Total debt increased $204 million from the end of 2024 to $1.194 billion, leading to a leverage ratio of 3.0 times adjusted EBITDA.
• The "Other Markets" segment sales decreased 15.5% in Q3 2025, primarily due to a planned multi-year exit from the portable medical market.
• Preliminary 2026 outlook anticipates potential declines in reported sales (down 2% to up 2%), adjusted operating income (down 5% to up 4%), and adjusted EPS (down 6% to up 5%) due to expected headwinds.
• Net cash provided by operating activities for the nine months ended September 26, 2025, slightly decreased to $140,733k from $141,974k in the prior year.

Risks

• Dependence upon a limited number of customers.
• Pricing pressures and contractual pricing restraints from customers.
• Reliance on third-party suppliers for raw materials, key products, and subcomponents.
• Potential for interruptions in manufacturing operations.
• Uncertainty surrounding macroeconomic and geopolitical factors.
• Ability to attract, train, and retain qualified associates.
• Potential for harm to reputation and competitive advantage due to quality problems.
• Dependence on information technology systems and vulnerability to cyber-attacks.
• Global climate change and emphasis on Environmental, Social, and Governance (ESG) matters.
• Dependence on senior management team and key technical personnel.
• Consolidation in the healthcare industry leading to greater competition.
• Intense competition and ability to successfully market products.
• Ability to respond to changes in technology.
• Ability to develop new products and expand into new geographic and product markets.
• Ability to successfully identify, make, and integrate acquisitions.
• Ability to accurately forecast future performance due to fluctuating operating results.
• Significant amount of outstanding indebtedness and ability to comply with financial covenants.
• Economic and credit market uncertainties that could interrupt access to capital markets.
• Conditional conversion features of Convertible Notes adversely impacting liquidity.
• Conversion of Convertible Notes diluting ownership interests of existing common stock holders.
• Counterparty risk associated with capped call transactions.
• Financial and market risks related to international sales and operations.
• Complex international tax profile.
• Ability to realize the full value of intangible assets.
• Regulatory issues from product complaints, recalls, or regulatory audits.
• Potential for product liability or intellectual property claims.
• Ability to protect intellectual property and proprietary rights.
• Ability to comply with customer-driven policies and third-party standards.
• Ability to obtain and/or retain necessary licenses for new technologies.
• Costs and ability to comply with environmental regulations.
• Legal and regulatory risks from international operations.
• Highly regulated healthcare industry subject to various regulatory changes.
• Indirect subjection to healthcare industry cost containment measures that could reduce product sales.

Future Outlook

The company updated its 2025 outlook, projecting sales between $1,840 million and $1,854 million, representing 7% to 8% growth, and non-GAAP adjusted EPS between $6.29 and $6.43, an increase of 19% to 21%. For 2026, preliminary guidance indicates reported sales could range from a 2% decrease to a 2% increase, with adjusted operating income potentially down 5% to up 4%, and adjusted EPS down 6% to up 5%, primarily due to anticipated headwinds. Looking further ahead to 2027, the company expects a return to strong organic sales growth, projecting 200 basis points above market.

Management Comments

• "Integer delivered another strong quarter of growth with sales up 8%, adjusted operating income up 14%, and adjusted EPS growth of 25%."
• "While select headwinds are expected to impact our 2026 sales, we believe our strategy and strong product development pipeline will lead to a return to 200 basis points above-market organic growth in 2027."

Industry Context

Integer Holdings Corporation operates as a leading medical device contract development and manufacturing organization (CDMO). The strong performance in its Cardio & Vascular segment, driven by new product ramps and acquisitions, aligns with the growing demand for advanced medical devices, particularly in electrophysiology and neurovascular. The planned exit from the portable medical market reflects a strategic focus on higher-growth, higher-margin core medical device segments. The anticipated headwinds for 2026, followed by a projected return to above-market organic growth in 2027, suggest a dynamic industry landscape where strategic positioning and product innovation are crucial for sustained success. The company's focus on PMA products in neuromodulation also indicates a move towards more advanced and regulated medical device solutions.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess the company's performance against global benchmarks. However, the company's stated goal of returning to "200 basis points above-market organic growth in 2027" implies an internal benchmark against overall medical device market growth, suggesting an ambition to outperform the industry average in the long term.

Stakeholder Impact

• Shareholders: Positive impact from strong Q3 performance, increased adjusted EPS, and raised 2025 outlook. Potential for dilution from Convertible Notes conversion is a risk.
• Employees: Potential for restructuring-related charges and termination benefits (mentioned in "Other general expenses" for 2025) indicates some workforce adjustments.
• Customers: Continued strong demand in key segments like Cardio & Vascular and emerging neuromodulation suggests positive customer relationships and product adoption.
• Suppliers: Reliance on third-party suppliers is a noted operational risk.
• Creditors: Increased total debt and leverage ratio, but the company is managing its financial structure, including convertible notes.

Next Steps

• Host a conference call on October 23, 2025, at 8 a.m. CT / 9 a.m. ET to discuss the Q3 2025 results.
• Make the updated Earnings Conference Call slide presentation available on the company's website under Investor Relations News & Events.
• Continue to execute on strategy and product development pipeline to achieve 200 basis points above-market organic growth in 2027.

Key Dates

Recommendation

The company delivered strong Q3 2025 results and raised its 2025 outlook, which are positive indicators. However, the preliminary 2026 outlook suggests potential headwinds and a period of slower growth or even slight declines in sales and adjusted EPS. The increase in debt to finance acquisitions and convertible notes also warrants careful consideration of the leverage ratio. While the long-term 2027 outlook is optimistic, the near-term uncertainty for 2026 suggests a "hold" position until there is more clarity on how the company navigates the anticipated headwinds and executes on its strategic initiatives to return to above-market growth.

Keywords

Medical device, CDMO, Contract manufacturing, Cardiac rhythm management, Neuromodulation, Cardio & Vascular, Electrophysiology, Neurovascular, Financial results, Earnings, Outlook, SEC filing, 8-K, Integer Holdings Corporation, ITGR